Treatments for newly diagnosed multiple myeloma: when endurance is interrupted

Affiliations

¹ Myeloma Program, Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL 33136, USA. Electronic address: col15@miami.edu.
² HMH School of Medicine, John Theurer Cancer Center, Hackensack, NJ, USA.
³ Lymphoid Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
⁴ Division of Hematology and Oncology, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, USA.
⁵ Myeloma Program, University of Chicago, Chicago, IL, USA.

Comment

Ola Landgren et al. Lancet Oncol. 2020 Dec.

. 2020 Dec;21(12):e540.

doi: 10.1016/S1470-2045(20)30635-5.

¹ Myeloma Program, Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL 33136, USA. Electronic address: col15@miami.edu.
² HMH School of Medicine, John Theurer Cancer Center, Hackensack, NJ, USA.
³ Lymphoid Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
⁴ Division of Hematology and Oncology, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, USA.
⁵ Myeloma Program, University of Chicago, Chicago, IL, USA.

No abstract available

Comment in

Treatments for newly diagnosed multiple myeloma: when endurance is interrupted - Authors' reply.
Kumar SK, Jacobus SJ, Rajkumar SV. Kumar SK, et al. Lancet Oncol. 2020 Dec;21(12):e541. doi: 10.1016/S1470-2045(20)30695-1. Lancet Oncol. 2020. PMID: 33271098 No abstract available.

Carfilzomib or bortezomib in combination with lenalidomide and dexamethasone for patients with newly diagnosed multiple myeloma without intention for immediate autologous stem-cell transplantation (ENDURANCE): a multicentre, open-label, phase 3, randomised, controlled trial.
Kumar SK, Jacobus SJ, Cohen AD, Weiss M, Callander N, Singh AK, Parker TL, Menter A, Yang X, Parsons B, Kumar P, Kapoor P, Rosenberg A, Zonder JA, Faber E Jr, Lonial S, Anderson KC, Richardson PG, Orlowski RZ, Wagner LI, Rajkumar SV. Kumar SK, et al. Lancet Oncol. 2020 Oct;21(10):1317-1330. doi: 10.1016/S1470-2045(20)30452-6. Epub 2020 Aug 28. Lancet Oncol. 2020. PMID: 32866432 Free PMC article. Clinical Trial.